-
circPTPN22 attenuates immune microenvironment of pancreatic cancer via STAT3 acetylation
Author: He, Yuan; Han, Pengyong; Chen, Chuang; Xie, Shuzhe; Zhang, Huiqing; Song, Yingming; Hu, Hao; Zhao, Qiang; Lian, Changhong
Journal: CANCER GENE THERAPY. 2023; Vol. 30, Issue 4, pp. 559-566. DOI: 10.1038/s41417-021-00382-w
-
FTO promotes Bortezomib resistance via m6A-dependent destabilization of SOD2 expression in multiple myeloma
Author: Wang, Chong; Li, Lingling; Li, Mengya; Wang, Weiqiong; Jiang, Zhongxing
Journal: CANCER GENE THERAPY. 2023; Vol. 30, Issue 4, pp. 622-628. DOI: 10.1038/s41417-022-00429-6
-
SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
Author: Du, Li; Liu, Wei; Pichiorri, Flavia; Rosen, Steven T.
Journal: CANCER GENE THERAPY. 2023; Vol. 30, Issue 4, pp. 567-574. DOI: 10.1038/s41417-022-00450-9
-
Protein post-translational modifications in the regulation of cancer hallmarks
Author: Wang, Haiying; Yang, Liqian; Liu, Minghui; Luo, Jianyuan
Journal: CANCER GENE THERAPY. 2023; Vol. 30, Issue 4, pp. 529-547. DOI: 10.1038/s41417-022-00464-3
-
Application of ATAC-seq in tumor-specific T cell exhaustion
Author: Chen, Chufeng; Liu, Jiaying; Chen, Yidong; Lin, Anqi; Mou, Weiming; Zhu, Lingxuan; Yang, Tao; Cheng, Quan; Zhang, Jian; Luo, Peng
Journal: CANCER GENE THERAPY. 2023; Vol. 30, Issue 1, pp. 1-10. DOI: 10.1038/s41417-022-00495-w
-
Lycium barbarum glycopeptide targets PER2 to inhibit lipogenesis in glioblastoma by downregulating SREBP1c
Author: Yao, Jian; Hui, Jian-wen; Chen, Yan-jun; Luo, Dong-yang; Yan, Jiang-shu; Zhang, Yi-fan; Lan, Yuan-xiang; Yan, Xiu-rui; Wang, Zhi-hua; Fan, Heng; Xia, Xe-chun
Journal: CANCER GENE THERAPY. 2023; Vol. , Issue , pp. -. DOI: 10.1038/s41417-023-00611-4
-
CDK5RAP3 acts as a tumour suppressor in gastric cancer through the infiltration and polarization of tumour-associated macrophages
Author: Wang, Jia-Bin; Gao, You-Xin; Ye, Yin-Hua; Lin, Tong-Xing; Li, Ping; Lin, Jian-Xian; Chen, Qi-Yue; Cao, Long-Long; Lin, Mi; Tu, Ru-Hong; Lin, Ju-Li; Huang, Ze-Ning; Zheng, Hua-Long; Xie, Jian-Wei; Zheng, Chao-Hui; Huang, Chang-Ming
Journal: CANCER GENE THERAPY. 2023; Vol. 30, Issue 1, pp. 22-37. DOI: 10.1038/s41417-022-00515-9
-
ECT2 promotes malignant phenotypes through the activation of the AKT/mTOR pathway and cisplatin resistance in cervical cancer
Author: Liu, Xiaoli; Zhang, Junhua; Ju, Shuang; Liu, Lu; Sun, Yu; Guo, Lingyu; Zhen, Qianwei; Han, Sai; Lu, Wei; Zhang, Youzhong
Journal: CANCER GENE THERAPY. 2023; Vol. 30, Issue 1, pp. 62-73. DOI: 10.1038/s41417-022-00525-7
